Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association with Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer

Clinical Breast Cancer

Volumn 16, Issue 1, 2016, Pages 51-58

  Park, In Hae ^a   Kong, Sun Young ^a   Ro, Jae Yoon ^b   Kwon, Youngmee ^a   Kang, Joo Hyun ^a   Mo, Hye Jin ^a   Jung, So Youn ^a   Lee, Seeyoun ^a   Lee, Keun Seok ^a   Kang, Han Sung ^a   Lee, Eunsook ^a   Joo, Jungnam ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hormone receptor; Immunohistochemistry; PD L1; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; BIOSYNTHESIS; BREAST TUMOR; CD8+ T LYMPHOCYTE; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIGENS, CD274; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84952876758     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.07.006     Document Type: Article

References (31)

1. L.A. Liotta, and E.C. Kohn The microenvironment of the tumor-host interface Nature 411 2001 375 379
2. K.E. de Visser, A. Eichten, and L.M. Coussens Paradoxical roles of the immune system during cancer development Nat Rev Cancer 6 2006 24 37
3. M.L. Disis Immune regulation of cancer J Clin Oncol 28 2010 4531 4538
4. S. Loi, N. Sirtaine, F. Piette, and et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG02-98 J Clin Oncol 31 2013 860 867
5. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, and et al. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
6. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
7. G.J. Bates, S.B. Fox, C. Han, and et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse J Clin Oncol 24 2006 5373 5380
8. A.N. Seo, H.J. Lee, E.J. Kim, and et al. Tumor infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer Br J Cancer 109 2013 2705 2713
9. H.R. Ali, E. Provenzano, S.J. Dawson, and et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients Ann Oncol 25 2014 1536 1543
10. S. Demaria, M.D. Volm, R.L. Shapiro, and et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy Clin Cancer Res 7 2001 3025 3030
11. C. Denkert, S. Loibl, A. Noske, and et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 2010 105 113
12. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 21 2011 480 489
13. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
14. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
15. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
16. J. Hamanishi, M. Mandai, M. Iwasaki, and et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365
17. J. Konishi, Y. Yamazaki, M. Azuma, and et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
18. R. Karim, E.S. Jordanova, S.J. Piersma, and et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T cell infiltration and survival of patients with cervical carcinoma Clin Cancer Res 15 2009 6341 6347
19. V. Velcheti, K.A. Schalper, D.E. Carvajal, and et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 2014 107 116
20. Q. Gao, X.Y. Wang, S.J. Qui, and et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 2009 971 979
21. M.E. Hammond, D.F. Hayes, M. Dowsett, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795
22. L.M. McShane, D.G. Altman, W. Sauerbrei, and et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
23. K.S. McCarty Jr., E. Szabo, J.L. Flowers, and et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors Cancer Res 46 8 suppl 1986 4244s 4248s
24. S. Muenst, A.R. Schaerli, F. Gao, and et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer Breast Cancer Res Treat 146 2014 15 24
25. E.A. Mittendorf, A.V. Philips, F. Meric-Berstam, and et al. PD-L1 expression in triple negative breast cancer Cancer Immunol Res 2 2014 361 370
26. H. Wimberly, J.R. Brown, K. Scalper, and et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer Cancer Immunol Res 3 2015 326 332
27. S. Spranger, R.M. Spaapen, Y. Zha, and et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells Sci Transl Med 5 2013 200ra116
28. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra37
29. C.T. Victor, A.J. Rech, A. Maity, and et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 2015 373 377
30. R.H. Thompson, S.M. Kuntz, B.C. Leibovich, and et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
31. R. Salgado, C. Denkert, S. Demaria, and et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014 Ann Oncol 26 2015 259 271 10.1093/annonc/mdu450 Accessed: September 7, 2015